Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma

Loading...
Thumbnail Image
File version

Accepted Manuscript (AM)

Author(s)
Lepletier, A
Madore, J
O'Donnell, JS
Johnston, RL
Li, XY
McDonald, E
Ahern, E
Kuchel, A
Eastgate, M
Pearson, SA
Mallardo, D
Ascierto, PA
Massi, D
Merelli, B
Mandala, M
Wilmott, JS
Menzies, AM
Leduc, C
Stagg, J
Routy, B
Long, GV
Scolyer, RA
Bald, T
Waddell, N
Dougall, WC
Teng, MWL
Smyth, MJ
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2020
Size
File type(s)
Location
License
Abstract

Purpose: Resistance to anti-PD1–based immune checkpoint blockade (ICB) remains a problem for the treatment of metastatic melanoma. Tumor cells as well as host myeloid cells can express the immune checkpoint ligand CD155 to regulate immune cell function. However, the effect of tumor CD155 on the immune context of human melanoma has not been well described. This observational study characterizes tumor CD155 ligand expression by metastatic melanoma tumors and correlates results with differences in immune cell features and response to ICB. Experimental Design: Pretreatment tumor specimens, from 155 patients with metastatic melanoma treated with ICB and from 50 patients treated with BRAF/MEK-directed targeted therapy, were assessed for CD155 expression by IHC. Intratumor T-cell features were analyzed using multiplex-immunohistofluorescence for CD8, PD1, and SOX10. Correlations were made between CD155 tumor level and bulk tumor RNA sequencing results, as well as clinical RECIST response and progression-free survival. Results: High pretreatment CD155 tumor levels correlated with high parenchymal PD1+CD8+/CD8+ T-cell ratios (PD1tR) and poor response to anti-PD1 therapy. In PDL1 negative tumors, high CD155 tumor expression was associated with patients who had poor response to combination anti-PD1/CTLA4 therapy. Conclusions: Our findings are the first to suggest that tumor CD155 supports an increase in the fraction of PD1+CD8+ T cells in anti-PD1 refractory melanoma tumors and, further, that targeting the CD155 pathway might improve response to anti-PD1 therapy for patients with metastatic melanoma.

Journal Title

Clinical Cancer Research

Conference Title
Book Title
Edition
Volume
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement

© 2020 AACR. This is the author-manuscript version of the paper. Reproduced in accordance with the copyright policy of the publisher. Please refer to the journal link for access to the definitive, published version.

Item Access Status
Note

This publication has been entered into Griffith Research Online as an Advanced Online Version.

Access the data
Related item(s)
Subject

Oncology and carcinogenesis

Persistent link to this record
Citation

Lepletier, A; Madore, J; O'Donnell, JS; Johnston, RL; Li, X-Y; McDonald, E; Ahern, E; Kuchel, A; Eastgate, M; Pearson, S-A; Mallardo, D; Ascierto, PA; Massi, D; Merelli, B; Mandala, M; Wilmott, JS; Menzies, AM; Leduc, C; Stagg, J; Routy, B; Long, GV; Scolyer, RA; Bald, T; Waddell, N; Dougall, WC; Teng, MWL; Smyth, MJ, Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma, Clinical Cancer Research, 2020

Collections